Arcturus Therapeutics Holdings, Inc. (ARCT)
10.35
+0.99
(+10.58%)
USD |
NASDAQ |
Nov 06, 16:00
10.36
+0.01
(+0.10%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (Quarterly) : 15.88M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 15.88M |
| June 30, 2026 | 17.12M |
| March 31, 2026 | 20.92M |
| December 31, 2025 | 21.89M |
| September 30, 2025 | 19.38M |
| June 30, 2025 | 25.75M |
| March 31, 2025 | 28.28M |
| December 31, 2024 | 28.41M |
| September 30, 2024 | 27.10M |
| June 30, 2024 | 36.34M |
| March 31, 2024 | 32.84M |
| December 31, 2023 | 26.82M |
| September 30, 2023 | 26.18M |
| June 30, 2023 | 32.98M |
| March 31, 2023 | 28.94M |
| December 31, 2022 | 24.48M |
| September 30, 2022 | 37.19M |
| June 30, 2022 | 36.89M |
| March 31, 2022 | 43.49M |
| December 31, 2021 | 31.93M |
| September 30, 2021 | 43.80M |
| June 30, 2021 | 44.78M |
| March 31, 2021 | 47.65M |
| December 31, 2020 | 25.09M |
| September 30, 2020 | 21.40M |
| Date | Value |
|---|---|
| June 30, 2020 | 12.64M |
| March 31, 2020 | 10.42M |
| December 31, 2019 | 11.99M |
| September 30, 2019 | 7.053M |
| June 30, 2019 | 7.269M |
| March 31, 2019 | 7.324M |
| December 31, 2018 | 4.847M |
| September 30, 2018 | 3.969M |
| June 30, 2018 | 4.225M |
| March 31, 2018 | 3.941M |
| December 31, 2017 | 11.36M |
| September 30, 2017 | 1.059M |
| June 30, 2017 | 1.443M |
| March 31, 2017 | 2.06M |
| December 31, 2016 | 4.447M |
| September 30, 2016 | 6.40M |
| June 30, 2016 | 4.182M |
| March 31, 2016 | 3.362M |
| December 31, 2015 | 3.335M |
| September 30, 2015 | 2.853M |
| June 30, 2015 | 3.683M |
| March 31, 2015 | 3.59M |
| December 31, 2014 | 4.908M |
| September 30, 2014 | 8.757M |
| June 30, 2014 | 5.918M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| Emergent BioSolutions, Inc. | 7.50M |
| Ionis Pharmaceuticals, Inc. | 216.41M |
| United Therapeutics Corp. | 279.20M |
| Ocugen, Inc. | 12.50M |